AcquisitionsJun 4, 2026, 08:06 AM
Kairos Pharma Acquires CL-741; Details 2026 Milestones
AI Summary
Kairos Pharma announced the acquisition of worldwide rights for CL-741, a Phase 1-ready c-MET kinase inhibitor targeting EGFR-mutated lung cancer, from Celyn Therapeutics. This addition expands its oncology pipeline, which includes ENV-105, KROS-201, KROS-102, and ENV-205. The company also outlined key milestones for the remainder of 2026, including initiating a Phase 1 study for CL-741 and advancing clinical trials for ENV-105.
Key Highlights
- Acquired worldwide rights for CL-741, a Phase 1-ready c-MET kinase inhibitor, from Celyn Therapeutics.
- CL-741 targets EGFR-mutated lung cancer, a market valued at an estimated $16.2 billion in 2026.
- Plans to initiate a Phase 1 study for CL-741 targeting EGFR-mutated lung cancer.
- Continuing Phase 2 clinical trial of ENV-105 in prostate cancer, with more sites expected.
- Continuing Phase 1 clinical trial of ENV-105 in NSCLC, aiming for safety and efficacy results by Q3 2026.
- Developing collaborations for ENV-105 synergy in prostate cancer by Q2/Q3 2026.
- Maintains a low monthly burn rate with over $8 million in non-dilutive funding.
Price Impact
More from KAPA